168 related articles for article (PubMed ID: 25246998)
1. Fcgbp - A Potential Viral Trap in RV144.
Schwartz JL
Open AIDS J; 2014; 8():21-4. PubMed ID: 25246998
[TBL] [Abstract][Full Text] [Related]
2. Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges.
Hessell AJ; Shapiro MB; Powell R; Malherbe DC; McBurney SP; Pandey S; Cheever T; Sutton WF; Kahl C; Park B; Zolla-Pazner S; Haigwood NL
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514914
[TBL] [Abstract][Full Text] [Related]
3. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.
Gottardo R; Bailer RT; Korber BT; Gnanakaran S; Phillips J; Shen X; Tomaras GD; Turk E; Imholte G; Eckler L; Wenschuh H; Zerweck J; Greene K; Gao H; Berman PW; Francis D; Sinangil F; Lee C; Nitayaphan S; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Tartaglia J; Robb ML; Michael NL; Kim JH; Zolla-Pazner S; Haynes BF; Mascola JR; Self S; Gilbert P; Montefiori DC
PLoS One; 2013; 8(9):e75665. PubMed ID: 24086607
[TBL] [Abstract][Full Text] [Related]
4. Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection.
Acharya P; Tolbert WD; Gohain N; Wu X; Yu L; Liu T; Huang W; Huang CC; Kwon YD; Louder RK; Luongo TS; McLellan JS; Pancera M; Yang Y; Zhang B; Flinko R; Foulke JS; Sajadi MM; Kamin-Lewis R; Robinson JE; Martin L; Kwong PD; Guan Y; DeVico AL; Lewis GK; Pazgier M
J Virol; 2014 Nov; 88(21):12895-906. PubMed ID: 25165110
[TBL] [Abstract][Full Text] [Related]
5. V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.
Perez LG; Martinez DR; deCamp AC; Pinter A; Berman PW; Francis D; Sinangil F; Lee C; Greene K; Gao H; Nitayaphan S; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Tartaglia J; O'Connell RJ; Robb ML; Michael NL; Kim JH; Gilbert P; Montefiori DC
PLoS One; 2017; 12(7):e0180720. PubMed ID: 28678869
[TBL] [Abstract][Full Text] [Related]
6. HIV-specific antibody immunity mediated through NK cells and monocytes.
Kramski M; Parsons MS; Stratov I; Kent SJ
Curr HIV Res; 2013 Jul; 11(5):388-406. PubMed ID: 24191935
[TBL] [Abstract][Full Text] [Related]
7. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.
Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431
[TBL] [Abstract][Full Text] [Related]
8. HIV vaccines: progress to date.
Munier CM; Andersen CR; Kelleher AD
Drugs; 2011 Mar; 71(4):387-414. PubMed ID: 21395355
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI
J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403
[TBL] [Abstract][Full Text] [Related]
10. CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.
Dommaraju K; Kijak G; Carlson JM; Larsen BB; Tovanabutra S; Geraghty DE; Deng W; Maust BS; Edlefsen PT; Sanders-Buell E; Ratto-Kim S; deSouza MS; Rerks-Ngarm S; Nitayaphan S; Pitisuttihum P; Kaewkungwal J; O'Connell RJ; Robb ML; Michael NL; Mullins JI; Kim JH; Rolland M
PLoS One; 2014; 9(10):e111334. PubMed ID: 25350851
[TBL] [Abstract][Full Text] [Related]
11. Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations.
Akapirat S; Karnasuta C; Vasan S; Rerks-Ngarm S; Pitisuttithum P; Madnote S; Savadsuk H; Rittiroongrad S; Puangkaew J; Phogat S; Tartaglia J; Sinangil F; de Souza MS; Excler JL; Kim JH; Robb ML; Michael NL; Ngauy V; O'Connell RJ; Karasavvas N;
PLoS One; 2018; 13(4):e0196397. PubMed ID: 29702672
[TBL] [Abstract][Full Text] [Related]
12. Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial.
Pitisuttithum P; Nitayaphan S; Chariyalertsak S; Kaewkungwal J; Dawson P; Dhitavat J; Phonrat B; Akapirat S; Karasavvas N; Wieczorek L; Polonis V; Eller MA; Pegu P; Kim D; Schuetz A; Jongrakthaitae S; Zhou Y; Sinangil F; Phogat S; Diazgranados CA; Tartaglia J; Heger E; Smith K; Michael NL; Excler JL; Robb ML; Kim JH; O'Connell RJ; Vasan S;
Lancet HIV; 2020 Apr; 7(4):e238-e248. PubMed ID: 32035516
[TBL] [Abstract][Full Text] [Related]
13. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines.
Chung AW; Ghebremichael M; Robinson H; Brown E; Choi I; Lane S; Dugast AS; Schoen MK; Rolland M; Suscovich TJ; Mahan AE; Liao L; Streeck H; Andrews C; Rerks-Ngarm S; Nitayaphan S; de Souza MS; Kaewkungwal J; Pitisuttithum P; Francis D; Michael NL; Kim JH; Bailey-Kellogg C; Ackerman ME; Alter G
Sci Transl Med; 2014 Mar; 6(228):228ra38. PubMed ID: 24648341
[TBL] [Abstract][Full Text] [Related]
14. Is developing an HIV-1 vaccine possible?
Haynes BF; Liao HX; Tomaras GD
Curr Opin HIV AIDS; 2010 Sep; 5(5):362-7. PubMed ID: 20978375
[TBL] [Abstract][Full Text] [Related]
15. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
[TBL] [Abstract][Full Text] [Related]
16. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.
Karasavvas N; Billings E; Rao M; Williams C; Zolla-Pazner S; Bailer RT; Koup RA; Madnote S; Arworn D; Shen X; Tomaras GD; Currier JR; Jiang M; Magaret C; Andrews C; Gottardo R; Gilbert P; Cardozo TJ; Rerks-Ngarm S; Nitayaphan S; Pitisuttithum P; Kaewkungwal J; Paris R; Greene K; Gao H; Gurunathan S; Tartaglia J; Sinangil F; Korber BT; Montefiori DC; Mascola JR; Robb ML; Haynes BF; Ngauy V; Michael NL; Kim JH; de Souza MS;
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1444-57. PubMed ID: 23035746
[TBL] [Abstract][Full Text] [Related]
17. Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies.
Doran RC; Tatsuno GP; O'Rourke SM; Yu B; Alexander DL; Mesa KA; Berman PW
PLoS One; 2018; 13(4):e0196370. PubMed ID: 29689099
[TBL] [Abstract][Full Text] [Related]
18. FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.
Li SS; Gilbert PB; Tomaras GD; Kijak G; Ferrari G; Thomas R; Pyo CW; Zolla-Pazner S; Montefiori D; Liao HX; Nabel G; Pinter A; Evans DT; Gottardo R; Dai JY; Janes H; Morris D; Fong Y; Edlefsen PT; Li F; Frahm N; Alpert MD; Prentice H; Rerks-Ngarm S; Pitisuttithum P; Kaewkungwal J; Nitayaphan S; Robb ML; O'Connell RJ; Haynes BF; Michael NL; Kim JH; McElrath MJ; Geraghty DE
J Clin Invest; 2014 Sep; 124(9):3879-90. PubMed ID: 25105367
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and immunological roles of Fc fragment of IgG binding protein in colorectal cancer.
Zhuang Q; Shen A; Liu L; Wu M; Shen Z; Liu H; Cheng Y; Lin X; Wu X; Lin W; Li J; Han Y; Chen X; Chen Q; Peng J
Oncol Lett; 2021 Jul; 22(1):526. PubMed ID: 34055091
[TBL] [Abstract][Full Text] [Related]
20. Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques.
Devasundaram S; Rosati M; Valentin A; Weiss S; Itri V; Trinh HV; Bear J; Chowdhury B; LaBranche CC; Montefiori D; Ferrari G; Rao M; Kong XP; Zolla-Pazner S; Pavlakis GN; Felber BK
J Virol; 2020 Dec; 95(2):. PubMed ID: 33087466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
